Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02374931
18F-FES PET/CT in Imaging Patients With Desmoid Tumors
Overview
This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.
Sponsor
Vanderbilt-Ingram Cancer Center
Phase
Early Phase 1
Contacts
Ashish Patel, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT02374931Drug / Compound
16 alpha-fluoroestradiol
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Estrogen Receptor
Ligand Class: Small Molecules
Eligibility
Inclusion
- Patients with biopsy-proven extra-abdominal desmoid tumors
- Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included
- No anti-estrogen therapy for desmoid tumor within the past 6 months
- Not currently on estrogen medication for birth control, menopause, or other reason
Exclusion
- Patients who do not wish to participate
- Pregnancy or nursing patients
Share your feedback
Help us improve your experience